RE:Antibe Partnership to Accelerate Drug Pipelinemstrmnd wrote: Based on quality of data from existing studies, I would not be surprised if Antibe partnered with Big Pharma earlier than expected to accelerate entire drug pipeline
Antibe can conduct multiple Phase 3 clinical trials with their pipeline simultaneously with a pharma partner - Antibe took 7 years to get ATB-346 here, with a pharma partner, all 4 of their top patents can be accelerated into their respective markets
GLTA
That certainly is one potential angle and I'd welcome it.
But - I see a required path in order to open that up to us.
346(acute) seems to be straight forward.
352(acute) to also follow suit - but - we don't know the specific purpose intended for that drug (yet).
Then - the rest of the pipeline is what we'd call "long term" or chronic type indications (for the most part).
I think ATE needs to solve 346(chronic) before any partner would be interested in partnering on that pipeline. IBD, 340, respiratory and others ... all have the same likely issue - liver confusion.
So ... ATE is working on a hypothesis based on what they've learned (and are learning) from liver experts. Can they solve the liver confusion issue?
Therefore ...
Bring acute to market - and - show that H2S IP has value. and
Solve chronic to open up the rest of the funnel to the end-game. Then ... your angle is viable. IMO